Mounjaro eligibility criteria: do you qualify for treatment?

You've checked your BMI, here's what the number actually means for Mounjaro

Most people arrive at this question with a BMI figure already in hand and a reasonable hope that it will settle things. It's a fair instinct. The licensed eligibility threshold for Mounjaro is a BMI of 30 or above, and for adults with a BMI between 27 and 29.9, at least one weight-related condition brings you within scope. Conditions that count include type 2 diabetes, prediabetes, high blood pressure, dyslipidaemia (raised cholesterol or triglycerides) and obstructive sleep apnoea, among others. If you carry one of those diagnoses alongside a BMI above 27, the licence covers you.

That said, a BMI figure is a number on a chart, not a clinical decision. Your prescriber will look at your full health history: current medicines, previous or active conditions, any contraindications listed in the Mounjaro SmPC on the eMC, and whether the expected benefits outweigh any specific risks for you. For instance, a personal history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or previous pancreatitis all warrant a careful conversation rather than a straightforward yes.

One practical point: the BMI threshold for Mounjaro applies at the standard level for most adults, but UK guidance specifies that people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds are assessed at thresholds 2.5 kg/m² lower. A BMI of 27.5 with a weight-related condition, for example, brings you within scope if that adjustment applies to you. The NHS BMI calculator is a useful starting point for confirming your number.

NHS access vs private access: why the criteria are not the same

The Mounjaro licence is one thing. NICE's recommendation, which shapes NHS availability, is another, and the two are not identical.

NICE recommended tirzepatide in December 2024 (TA1026), but specifically for adults with a BMI of 35 or above plus at least one weight-related comorbidity, through specialist NHS weight management services. The ethnic-background thresholds apply here too, reducing the qualifying BMI by 2.5 kg/m². NHS England is rolling out access in phases: the first cohort (BMI 40 or above with four or more qualifying conditions) opened in June 2025, and a second cohort covering BMI 35 to 39.9 with four or more conditions activated in June 2026. Further phases are planned into 2027. Every NHS patient must also take part in wraparound diet and activity support; meeting the criteria does not automatically mean immediate access, and waiting times vary by area.

Private treatment through a regulated online pharmacy follows the licensed eligibility criteria rather than NICE's NHS thresholds, so adults with a BMI of 30 or above (or 27-plus with a qualifying condition) may be clinically suitable for private treatment even if they don't yet meet the NHS's stricter criteria. Details of what accessing Mounjaro privately involves are covered on the how to get Mounjaro page. For a broader look at all available options, the weight-loss treatments overview sets out the landscape clearly.

The NICE appraisal is publicly available for anyone who wants to read the exact wording: NICE TA1026, recommendations chapter.

What disqualifies someone, and what's often a misconception

A few conditions listed in Mounjaro's summary of product characteristics mean the medicine is not appropriate. Pregnancy, breastfeeding and actively trying to conceive are all situations where Mounjaro is not recommended. Under-18s are not within the licensed population. A history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication. Severe gastrointestinal conditions and a history of acute pancreatitis both require careful prescriber assessment rather than automatic exclusion, but they do add complexity.

A common misconception is that type 2 diabetes disqualifies you. It doesn't. Mounjaro is actually licensed for type 2 diabetes management as well as weight management, so the presence of diabetes does not rule out treatment, it may, depending on your current regimen, affect which medicines can be continued alongside it. That's precisely the kind of detail a prescriber works through with you.

Another misconception worth addressing: being above the BMI threshold but in otherwise good health is sometimes read as meaning treatment isn't needed. The science is clear that weight is a health condition shaped by biology, not a willpower question. The Mounjaro overview page covers how the medicine works and what the clinical evidence shows. For a deeper look at how eligibility maps to the clinical pathway, the full criteria breakdown adds useful context. Information on how tirzepatide's eligibility rules compare across different settings is also on the tirzepatide eligibility page.

What happens at the consultation, and what to have ready

If you think you meet the criteria, a free consultation with a GPhC-registered Independent Prescriber is the next step. At nume, a real clinician reviews your answers the same day, not software, not a queue. The consultation covers your BMI, relevant medical history, current medications and any conditions that need consideration. You'll go through photo ID verification and live weight confirmation on video, so there's no ambiguity about the starting point.

It helps to have your current medication list to hand and, if you've been treated elsewhere, details of your existing dose and any clinical evidence your new prescriber will need. If you're coming from a GP or specialist, our prescribers can work with that history rather than starting from scratch.

The cost of treatment, what's included and how pricing works at nume (sorry, at a private regulated pharmacy) is explained on the weight-loss eligibility and pricing page. When you're ready, you can check your eligibility and start your free consultation directly.